Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Ferring Pharmaceuticals' FIRMAGON® Named Official Sponsor of Ed Randall's Bat for the Cure

July 12, 2010 11:37 am | by Bio-Medicine.Org | News | Comments

PARSIPPANY, N.J. , July 12 /- Ferring Pharmaceuticals Inc., the makers of FIRMAGON® (degarelix for injection), will sponsor Ed Randall 's Bat for the Cure charity, in an effort to "strike-out prostate cancer" with awareness, education, effective management and prevention support at...

TOPICS:

Hanger Ivan R. Sabel Foundation to Receive $75,000 Donation Towards Charitable Prosthetic Efforts in Haiti from Grapes for Humanity/US

July 12, 2010 11:37 am | by Bio-Medicine.Org | News | Comments

BETHESDA, Md. , July 12 /- The Hanger Ivan R. Sabel Foundation today announced it will receive a generous donation of $75,000 from Grapes for Humanity/US, an internationally recognized charitable foundation that has raised millions of dollars in support of landmine survivors and innocent...

TOPICS:

DocNog California Mobile App Automates Medical Provider Search

July 12, 2010 11:37 am | by Bio-Medicine.Org | News | Comments

MURRIETA, Calif. , July 12 /- NogWorld LLC, a pioneer in mobile search technology, has launched DocNog, a mobile app designed to empower healthcare consumers to easily connect and access medical providers. The DocNog California App was recently featured in the "New and Noteworthy" section...

TOPICS:
Advertisement

Holon: The Process Adaptive Interoperability Framework

July 12, 2010 11:37 am | by Bio-Medicine.Org | News | Comments

ATLANTA , July 12 /- Holon, the new standard for healthcare interoperability, today announced general availability of its Medication Management solution. Leveraging the Holon Process Adaptive Interoperability Framework, Holon introduces a cost-effective alternative to your paper processes...

TOPICS:

Early diagnosis key in managing, treating bladder cancer

July 12, 2010 11:36 am | by Baylor College of Medicine | News | Comments

Early diagnosis of bladder cancer is critical to management and treatment of the disease and improving chances of survival, said a urologic oncologist from Baylor College of Medicine . "Bladder cancer is a highly treatable, highly curable disease particularly before it invades the...

TOPICS:

BCM researchers leading efforts in bladder cancer research

July 12, 2010 11:36 am | by Baylor College of Medicine | News | Comments

Researchers from Baylor College of Medicine's Scott Department of Urology , Department of Molecular and Cellular Biology and the NCI-designated Dan L. Duncan Cancer Center are leading major efforts in bladder cancer research, both in the clinical and lab setting. Find out more about...

TOPICS:

Older men with smoking history needed for bladder cancer screening study

July 12, 2010 11:36 am | by Baylor College of Medicine | News | Comments

Men over the age of 60 who have smoked for at least 20 years are being asked to participate in a bladder cancer screening study at Baylor College of Medicine . Currently, there is no established screening method for bladder cancer. "We want to find a way to detect the cancer early enough...

TOPICS:

Telik Announces Publication of Review Focused on the Inhibition of the Enzyme GSTP1-1 as a Target for New Cancer Treatments

July 12, 2010 11:36 am | by Bio-Medicine.Org | News | Comments

PALO ALTO, Calif. , July 12 /- Telik, Inc. (Nasdaq: TELK ) today announced the publication of a review in the journal, Cell Death and Differentiation : Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death;...

TOPICS:
Advertisement

Novelos revives failed drug as potential breast cancer treatment

July 12, 2010 11:34 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Novelos Therapeutics Inc. has announced positive Phase 2 results for NOV-002 to treat patients with certain types of breast cancer, following an earlier failure of the drug target to treat lung cancer.

TOPICS:

Lantheus Medical acquires global rights to ex-Epix product

July 12, 2010 11:34 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Diagnostic imaging firm Lantheus Medical Imaging Inc. has acquired global rights to Ablavar, a blood pool imaging agent used in patients with peripheral vascular disease and formerly owned by now-bankrupt Epix Pharmaceuticals Inc.

TOPICS:

Compliance Corner: As Good as Your Suppliers—Watch Out!

July 12, 2010 11:08 am | by Ken Appel | Blogs | Comments

To maintain the modicum of quality standards, many are re-discovering the reasons why the Japanese auto industry pioneered poka-yoke assembly techniques years ago—where extra steps are built into manufacturing processes to take the potential for errors by less-trained workers out of the equation.

Supreme Court Decision Could Help Protect Patents for Diagnostics

July 12, 2010 8:31 am | by U.S. Food & Drug Administration | News | Comments

Diagnostic companies seeking to patent a process or method used in product development may have an easier time doing so following a recent Supreme Court decision.

TOPICS:

Industry: The FDA Can Do More to Speed Development of HDEs

July 12, 2010 8:31 am | by U.S. Food & Drug Administration | News | Comments

Devicemakers are asking for more incentives and flexible standards as the FDA explores ways to encourage the development of devices to treat rare diseases.

TOPICS:

Accumetrics, Inc., Daiichi Sankyo, Inc. and Eli Lilly and Company Launch Strategic U.S. Collaboration

July 12, 2010 7:35 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO , PARSIPPANY, N.J. and INDIANAPOLIS , July 12 /- Accumetrics, Inc., Daiichi Sankyo, Inc, and Eli Lilly and Company announced today that the companies have entered into a strategic collaboration in the United States to raise awareness about antiplatelet therapy and the role of...

TOPICS:

Visterra takes in $6M VC funds, launches Singapore arm

July 12, 2010 7:34 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Cambridge biotech startup Visterra Inc., formerly known as Parasol Therapeutics, has landed $6 million in its first round of funding, which accompanied the launch of Visterra Singapore Pte. Ltd. from Visterra, the Singapore-MIT Alliance for Research and Technology (SMART) Center and the...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading